AF
AXSM icon

Amalgamated Financial’s Axsome Therapeutics AXSM Stock Holding History

Amalgamated Financial’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$187K Buy
+4,525
New +$140K ﹤0.01% 1925

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Amalgamated Financial's AXSM Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Axsome Therapeutics (AXSM) in Q1 2022: 4,525 shares worth $187K. The stake represents ﹤0.01% of the portfolio and ranks #1925 among its holdings.

174 funds tracked by Wall St. Rank hold AXSM as of Q1 2022.

  • Amalgamated Financial held 4,525 shares of Axsome Therapeutics worth $187K as of Q1 2022.
  • Axsome Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Axsome Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1925 holding.
  • 174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.